Emerging Markets Earnings Roundup: GSK (Part 9)
This article was originally published in PharmAsia News
GlaxoSmithKline executives spoke to the point about continued sales issues in China, but offered some guidance that its issues with a compliance scandal that started in July last year are stabilizing. CEO Andrew Witty spent much of his time talking about the massive deal with Novartis, leaving Simon Dingemans, chief financial officer, to fill in details on emerging markets.
You may also be interested in...
Working with partners, GSK aims to have at least two new cancer immunotherapies in the clinic by mid-2015, says Axel Hoos, the former BMS exec who developed the checkpoint grandfather Yervoy.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.